

# Valsartan is as safe and effective as enalapril for people with heart failure

Abstracted from: Willenheimer R, Helmers C, Pantev E et al. Safety and efficacy of valsartan versus enalapril in heart failure patients. *Int J Cardiol* 2002; 85: 261–270.

**BACKGROUND** ACE inhibitors are underused when treating heart failure, partly due to adverse effects. Angiotensin-receptor blockers may replace ACE inhibitors in heart failure, if similarly effective, because they are better tolerated.

**OBJECTIVE** To compare the safety and efficacy of valsartan and enalapril for people with heart failure stabilised on an ACE inhibitor.

**SETTING** Multiple centres; location and timeframe not specified.

**METHOD** Randomised trial.

**PARTICIPANTS** One hundred and forty-one adults with stable moderate or mild heart failure and left ventricular ejection fraction of 0.45 or less. Mean age 68 years (range 46 to 90); 26% women. All had been treated with an ACE inhibitor for at least 3 months and were able to perform a 6-minute walking test. Exclusion criteria were myocardial infarction or coronary intervention within 3 months; heart failure due to pulmonary disease; significant primary valvular disease; infective cardiomyopathy; unstable coronary disease; severe arrhythmia; recent stroke; significant laboratory abnormalities; other reason for limited exercise capacity angiotensin-receptor blocker

treatment within 3 months, and persistent systolic blood pressure less than 90 mmHg.

**INTERVENTION** One hundred and sixty milligrams of valsartan once daily or 10 mg enalapril twice daily for 12 weeks.

**MAIN OUTCOMES** Exercise capacity (using distance walked during 6-minute test); left ventricular size and function.

**MAIN RESULTS** There was no significant difference between groups in changes in the 6-minute walk test, patients' well-being, left ventricular size and function or adverse effects. Left ventricular size ( $p < 0.001$ ) and function ( $p = 0.05$ ) improved slightly from baseline in the valsartan group.

**AUTHORS' CONCLUSIONS** Valsartan is as safe and effective as enalapril for people with mild-to-moderate heart failure previously stabilised on an ACE inhibitor.

*Sources of funding:* Novartis Pharma.

*Correspondence to:* R. Willenheimer, Department of Cardiology, Malmo University Hospital, Sweden. E-mail: ronnie.willenheimer@medforsk.mas.lu.se

Abstract prepared by Bazian Ltd, London

## Commentary I

Renin–angiotensin system inhibition is widely used in heart failure. Inhibitors of the angiotensin converting enzyme (ACE-I) have been investigated in a number of randomised trials with more than 12 000 participants.<sup>1</sup> ACE inhibitors have become the cornerstone of present-day treatment of chronic heart failure.<sup>2</sup> ACE inhibitors work by blocking conversion of angiotensin I to angiotensin II and thereby preventing AT<sub>1</sub> receptor stimulation. AT<sub>1</sub> receptor blockers directly block the AT<sub>1</sub> receptor and are therefore more pharmacologically efficient than ACE inhibitors.<sup>3,4</sup>

Willenheimer and colleagues' findings support previous studies comparing ACE inhibitors and AT<sub>1</sub> receptor antagonists. ELITE, the first comparative trial, found nearly twice as many deaths in the captopril group as with losartan. The primary end-point, influence on renal function, remained unchanged, however.<sup>5</sup> This left open the question of whether AT<sub>1</sub> receptor blockers could replace ACE inhibitors in heart failure, a question examined in ELITE II.

The ELITE II trial was the first to compare mortality with ACE inhibitors and AT<sub>1</sub> blockers in chronic heart failure. ELITE II did not confirm the findings of the ELITE study, but was terminated after 530 deaths. The mean observation period was 555 days. Mortality was 15.9% for captopril and 17.7% for losartan ( $p = 0.16$ ). Thus, losartan did not improve survival over captopril, although early termination meant that the study may have lacked power to detect a clinically important difference in mortality.<sup>6</sup>

The RESOLVD study was terminated prematurely due to higher mortality in people receiving candesartan plus enalapril compared to enalapril or candesartan alone.<sup>7</sup> In this study, enalapril was more efficacious than candesartan alone, but differences in mortality and number of hospital stays did not reach statistical significance.

The ValHeFT study assessed the long-term effect of the angiotensin II receptor blocker, valsartan, when added to standard heart failure therapy (including ACE-I). There was no difference in all-cause mortality. The combined end-point of mortality plus morbidity was 13.2% lower with valsartan, mainly due to reductions in the number of hospital stays due to heart failure.<sup>8</sup>

This study by Willenheimer and colleagues found that 12 weeks of valsartan and enalapril had a similar effect on exercise capacity, symptoms of heart failure, quality of life and left ventricular function and size. Exercise end-points are related to quality of life rather than mortality. Thus, the study reinforces what we already know: that ACE-I and angiotensin II receptor blockers

are comparable and well tolerated. Further studies comparing ACE-I with angiotensin II receptor blockers using surrogate end-points are unlikely to unearth anything new. Angiotensin II receptor blockers are no more effective than ACE-I inhibitors for chronic heart failure. As Reimer and Califf say, this is 'good news for [an] experimental concept but bad news for clinically effective therapy'<sup>9</sup>.

**Professor Jiri Vitovec**, MD, PhD, FESC  
1st Department of Medicine – Cardioangiology,  
St Anne's University Hospital,  
Czech Republic

### Literature cited

1. Flather MD, Yusuf S, Käber L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricle dysfunction: a systematic overview of data from individual patients. *Lancet* 2000; 355: 1575–1580.
2. Braunwald E. ACE inhibitors: a cornerstone of the treatment of heart failure. *N Engl J Med* 1991; 325: 351–353.
3. Csikos T, Chung O, Unger T. Receptors and their classification: focus on angiotensin II and the AT<sub>2</sub> receptor. *J Hum Hypertens* 1998; 12: 311–318.
4. Willenheimer R, Dahlof B, Rydberg E, Erhardt L. AT<sub>1</sub>-receptor blockers in hypertension and heart failure: clinical experience and future directions. *Eur Heart J* 1999; 20: 997–1008.
5. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). *Lancet* 1997; 349: 747–752.
6. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000; 355: 1582–1587.
7. The RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomised evaluation strategies for left ventricular dysfunction (RESOLVD) pilot study. *Circulation* 1999; 100: 1056–1064.
8. Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001; 345: 1667–1675.
9. Reimer KA, Califf RA. Good news for experimental concept but bad news for clinically effective therapy. *Circulation* 1999; 99: 198–200.

## Commentary 2

The incidence and prevalence of chronic heart failure is increasing. The complexities of heart failure progression are not completely understood. One-year mortality for severe heart failure is about 36%.<sup>1</sup> Angiotensin-converting enzyme (ACE) inhibitors have become a standard treatment because large, long-term trials found marginally improved morbidity and mortality rates.<sup>2</sup> Angiotensin II receptor blockers (ARBs) like valsartan are among several classes of drugs being studied for people with chronic heart failure.<sup>3</sup> Valsartan was recently approved by the United States Food and Drug Administration for use in heart failure patients unable to tolerate ACE inhibitors.

The Val-HeFT trial compared 160 mg valsartan twice daily and placebo added to conventional therapy in 5010 people with chronic heart failure over a mean duration of 23 months.<sup>4</sup> Valsartan reduced the combined end-points of mortality and morbidity and improved clinical signs and symptoms. A post-hoc analysis in 1610 people receiving the triple combination of valsartan added to an ACE inhibitor and a  $\beta$ -blocker found an increased mortality rate compared to placebo ( $p = 0.009$ ). This result will require further investigation to determine its clinical implications.

This article by Willenheimer and colleagues examined whether people with mild-to-moderate stable heart failure could safely be switched directly from an ACE inhibitor to once daily valsartan (160 mg) for 12 weeks. There were no significant differences in exercise tolerance, New York Heart Association Class, dyspnea index, quality of life score or left ventricular chamber size from echocardiography. The study has no dramatic news for clinicians, but adds to our confidence that we can safely switch from an ACE inhibitor directly to valsartan in people with mild-to-moderate stable heart failure. This supports findings with other ARBs.<sup>5–7</sup>

In this study, the dose of valsartan was 160 mg once daily, just half the dose found to be most beneficial in an earlier dose-finding trial. This raises questions about the target dosage for this drug. There are also questions about the long-term safety and effectiveness of ARBs. Although current guidelines suggest that standard heart failure therapy should include an ACE inhibitor,<sup>2</sup>

it appears that ARBs may be appropriate for people intolerant of ACE inhibitors.

**Daniel R. Struckman**, PHARM D, BCPS  
School of Pharmacy,  
University of Michigan, Ann Arbor, USA

### Literature cited

1. Economic cost of cardiovascular diseases. American Heart Association, 2000. [www.americanheart.org/statistics/10econom.html](http://www.americanheart.org/statistics/10econom.html).
2. Martineau P, Goulet J. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure. *Ann Pharmacother* 2001; 35: 71–84.
3. Cohn JN, Tognoni G. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001; 345: 1667–1675.
4. Lang RM, Elkayam U, Yellen LG et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. *J Am Coll Cardiol* 1997; 30: 983–991.
5. Dickstein K, Chang P, Willenheimer R et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. *J Am Coll Cardiol* 1995; 26: 438–445.
6. Replacement of Angiotensin Converting Enzyme Inhibition (REPLACE) Investigators, Dunselman PH. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. *Int J Cardiol* 2001; 77: 131–140.
7. Baruch L, Anand I, Cohen IS et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. *Circulation* 1999; 99: 2658–2664.